大肠癌中CDC25B的表达与预后

为了探讨CDC2 5B在大肠癌发生、发展中的作用及其表达与大肠癌临床病理特征、病人预后的关系。采用免疫组化染色 (S P法 )对 168例大肠癌、2 5例大肠腺瘤、2 0例正常组织中CDC2 5B进行了检测。结果显示 ,大肠腺瘤、正常组织中均未见CDC2 5B表达。大肠癌组织中CDC2 5B基因表达阳性占 71 4% ( 12 0 /168)。CDC2 5B基因表达与癌有无远处脏器转移、血清CEA水平相关 (P <0 0 5 ) ,而与临床病理分期、组织分级、淋巴结转移、肿瘤大小、性别、年龄均无关(P >0 0 5 )。CDC2 5B基因阳性表达者 ,5年生存率明显降低。提示大肠癌组织中CDC2 5B基因表达可能加速细胞周期转化 ,促进大肠癌向远处脏器转移 ,在大肠癌发展中可能起一定作用 ,为大肠癌预后不良的危险因素

THE EXPRESSION OF CDC25B IN COLORECTAL CANCER AND ADENOMA AND ITS CLINICAL SIGNIFICANCE

To explore the role of CDC25B in pathogenesis and development of colorectal cancer and to investigate the relation between the expression of CDC25B and the clinical pathological character of colorectal cancer and the prognosis of patients. The expression of CDC25B in 168 patients with colorectal cancer and 25 patients with adenoma, and normal colorectal mucosa from 20 individuals was assayed by immunohistochemistry (S-P method). The expression of CDC25B was not detected in adenoma and normal colorectal mucosa. The expression rate of CDC25B in colorectal cancer was 71.4%(120/168). The expression of CDC25B had a positive correlation with distant metastasis and the increase of CEA,while it had no relationship with the tumor stage, grade, lymph node metastases, gender, age or the size of tumor . The patients in whom expression of CDC25B was detected had a markedly low 5-year survival rate. The results suggested that expression of CDC25B in colorectal cancer might accelerate the transformation of cell cycle,which promoted metastasis to distant organ, indicating that the expression of CDC25B might play a role in the development of colorectal cancer. The expression of CDC25B was a risk factor of poor prognosis.